Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher A Eide

Showing results (31-40 of 83) with videos related to

Pageof 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2014
Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemiaAnupriya Agarwal, Ryan J MacKenzie, Raffaella Pippa, et al.
Leukemia|February 26, 2020
Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemiaChristopher A Eide, Stephen E Kurtz, Andy Kaempf, et al.
Science Translational Medicine|September 2, 2016
Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemiaJessica T Leonard, Joelle S J Rowley, Christopher A Eide, et al.
Cancer Cell|December 16, 2011
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemiaLeisl M Packer, Sareena Rana, Robert Hayward, et al.
Cancer Research|July 24, 2021
Lentiviral-Driven Discovery of Cancer Drug Resistance MutationsPaul Yenerall, Rahul K Kollipara, Kimberley Avila, et al.
Blood|December 17, 2008
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patientsJeffrey W Tyner, Heidi Erickson, Michael W N Deininger, et al.
Science Translational Medicine|September 5, 2014
A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemiaLeyuan Ma, Yi Shan, Robert Bai, et al.
Science Signaling|July 19, 2018
Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemiaChelsea Jenkins, Samuel B Luty, Julia E Maxson, et al.
Cancer Research|June 3, 2015
Therapeutically Targetable ALK Mutations in LeukemiaJulia E Maxson, Monika A Davare, Samuel B Luty, et al.
Oncotarget|December 2, 2015
Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinomaHui-Wen Lue, Brook Cole, Soumya A M Rao, et al.
Pageof 9

Showing results (31-40 of 83) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2014
Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemiaAnupriya Agarwal, Ryan J MacKenzie, Raffaella Pippa, et al.
Leukemia|February 26, 2020
Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemiaChristopher A Eide, Stephen E Kurtz, Andy Kaempf, et al.
Science Translational Medicine|September 2, 2016
Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemiaJessica T Leonard, Joelle S J Rowley, Christopher A Eide, et al.
Cancer Cell|December 16, 2011
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemiaLeisl M Packer, Sareena Rana, Robert Hayward, et al.
Cancer Research|July 24, 2021
Lentiviral-Driven Discovery of Cancer Drug Resistance MutationsPaul Yenerall, Rahul K Kollipara, Kimberley Avila, et al.
Blood|December 17, 2008
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patientsJeffrey W Tyner, Heidi Erickson, Michael W N Deininger, et al.
Science Translational Medicine|September 5, 2014
A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemiaLeyuan Ma, Yi Shan, Robert Bai, et al.
Science Signaling|July 19, 2018
Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemiaChelsea Jenkins, Samuel B Luty, Julia E Maxson, et al.
Cancer Research|June 3, 2015
Therapeutically Targetable ALK Mutations in LeukemiaJulia E Maxson, Monika A Davare, Samuel B Luty, et al.
Oncotarget|December 2, 2015
Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinomaHui-Wen Lue, Brook Cole, Soumya A M Rao, et al.
Pageof 9